Initial focus will be on tools to help cancer diagnosis.
Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.
The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will, the companies report, enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.
